Technology
Health
Pharmaceutical

Xeris Pharmaceuticals

$10.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.40 (-3.81%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell XERS and other stocks, options, ETFs, and crypto commission-free!

About

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. Read More The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Employees
90
Headquarters
Chicago, Illinois
Founded
2005
Market Cap
218.49M
Price-Earnings Ratio
Dividend Yield
Average Volume
143.82K
High Today
$10.54
Low Today
$10.06
Open Price
$10.51
Volume
106.65K
52 Week High
$27.98
52 Week Low
$8.67

Collections

Technology
Health
Pharmaceutical
2018 IPO
US
North America

News

Associated PressMar 14

Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia

CHICAGO--(BUSINESS WIRE)--Mar 14, 2019--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia (EIH). “Many individuals with diabetes...

113
Simply Wall StFeb 26

What You Must Know About Xeris Pharmaceuticals, Inc.’s (NASDAQ:XERS) Financial Strength

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While small-cap stocks, such as Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) with its market cap of US$264m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. Companies operating in the Pharmaceuticals industry, especially ones that are currently loss-making, are more likely to be higher risk. So, under...

50
Markets InsiderFeb 20

Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference

CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference. Date: Wednesday, February 27, 2019 Time: 3:30 p.m. ET Place: L...

186

Earnings

-$0.98
-$0.89
-$0.80
-$0.71
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.94 per share
Actual
-$0.98 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.